Health Trials

KRAS G12D Mutations

2

Review clinical trials related to KRAS G12D Mutations. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

This is a multicenter, open-label, phase Ⅱa study to explore the safety, tolerability, and preliminary efficacy of RNK08954 in metastatic pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation.

Participants needed: 60
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Ranok Therapeutics (Hangzhou) Co., Ltd.Updated: Dec 24, 2025Locations: 2
Eligibility criteria

The subjects voluntarily joined the study and signed the informed consent, with... [+8]

Diagnosed with other pathological types of pancreatic tumors; [+17]

Read more
Status: Recruiting

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

This is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.

Participants needed: 407
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Genfleet Therapeutics (Shanghai) Inc.Updated: Nov 20, 2025Locations: 20
Eligibility criteria

Subjects must voluntarily agree to participate in the trial and sign a written i... [+6]

Active brain metastases. [+6]

Read more